Tialfi Bergamin de Castro1, Newton Antônio Bordin-Junior2, Eduardo Alves de Almeida3, Debora Aparecida Pires de Campos Zuccari4,5. 1. São Paulo State University - UNESP, Cristóvão Colombo, 2265, São José do Rio Preto, 15054-000, São Paulo, Brazil. 2. São José do Rio Preto Medical School - FAMERP, Av. Brigadeiro Faria Lima, 5416, São José do Rio Preto, 15090-000, São Paulo, Brazil. 3. Regional University of Blumenau Foundation - FURB, Antônio da Veiga, 140, Blumenau, 89030-903, Santa Catarina, Brazil. 4. São Paulo State University - UNESP, Cristóvão Colombo, 2265, São José do Rio Preto, 15054-000, São Paulo, Brazil. debora.zuccari@famerp.br. 5. São José do Rio Preto Medical School - FAMERP, Av. Brigadeiro Faria Lima, 5416, São José do Rio Preto, 15090-000, São Paulo, Brazil. debora.zuccari@famerp.br.
Abstract
PURPOSE: Changes in the circadian rhythm may contribute to the development of cancer and are correlated with the high risk of breast cancer (BC) in night workers. Melatonin is a hormone synthesized by the pineal gland at night in the absence of light. Levels of melatonin and the metabolite of oxidative metabolism AFMK (acetyl-N-formyl-5-methoxykynurenamine), are suggested as potential biomarkers of BC risk. The aims of this study were to evaluate levels of melatonin and AFMK in women recently diagnosed with BC, women under adjuvant chemotherapy, and night-shift nurses, and compare them with healthy women to evaluate the relation of these compounds with BC risk. METHODS: Blood samples were collected from 47 women with BC, 9 healthy women, 10 healthy night shift nurses, and 6 patients under adjuvant chemotherapy. Compound levels were measured by mass spectrometry. RESULTS AND CONCLUSIONS: Our results showed that women with BC had lower levels of melatonin compared to control group women, and even lower in night-shift nurses and in patients under adjuvant chemotherapy. There was no significant difference of AFMK levels between the groups. In addition to this, high levels of melatonin and AFMK were related to patients with metastasis, and high levels of AFMK were related to the presence of lymph node-positive, tumor > 20 mm and patients who sleep with light at night. Our results showed a reduction of melatonin levels in BC patients, suggesting a relation with the disease, and in addition, point to the importance of melatonin supplementation in women that work at night to reduce the BC risk.
PURPOSE: Changes in the circadian rhythm may contribute to the development of cancer and are correlated with the high risk of breast cancer (BC) in night workers. Melatonin is a hormone synthesized by the pineal gland at night in the absence of light. Levels of melatonin and the metabolite of oxidative metabolism AFMK (acetyl-N-formyl-5-methoxykynurenamine), are suggested as potential biomarkers of BC risk. The aims of this study were to evaluate levels of melatonin and AFMK in women recently diagnosed with BC, women under adjuvant chemotherapy, and night-shift nurses, and compare them with healthy women to evaluate the relation of these compounds with BC risk. METHODS: Blood samples were collected from 47 women with BC, 9 healthy women, 10 healthy night shift nurses, and 6 patients under adjuvant chemotherapy. Compound levels were measured by mass spectrometry. RESULTS AND CONCLUSIONS: Our results showed that women with BC had lower levels of melatonin compared to control group women, and even lower in night-shift nurses and in patients under adjuvant chemotherapy. There was no significant difference of AFMK levels between the groups. In addition to this, high levels of melatonin and AFMK were related to patients with metastasis, and high levels of AFMK were related to the presence of lymph node-positive, tumor > 20 mm and patients who sleep with light at night. Our results showed a reduction of melatonin levels in BC patients, suggesting a relation with the disease, and in addition, point to the importance of melatonin supplementation in women that work at night to reduce the BC risk.
Entities:
Keywords:
AFMK; Blood level; Breast cancer; Circadian rhythmic; Melatonin
Authors: Emilie Cordina-Duverger; Florence Menegaux; Alexandru Popa; Sylvia Rabstein; Volker Harth; Beate Pesch; Thomas Brüning; Lin Fritschi; Deborah C Glass; Jane S Heyworth; Thomas C Erren; Gemma Castaño-Vinyals; Kyriaki Papantoniou; Ana Espinosa; Manolis Kogevinas; Anne Grundy; John J Spinelli; Kristan J Aronson; Pascal Guénel Journal: Eur J Epidemiol Date: 2018-02-20 Impact factor: 8.082
Authors: K Melancon; Q Cheng; T L Kiefer; J Dai; L Lai; C Dong; L Yuan; A Collins; A Thiyagarajah; S Long; S M Hill Journal: Cancer Lett Date: 2005-09-08 Impact factor: 8.679
Authors: Gilles Ferry; Caroline Ubeaud; Pierre-Hervé Lambert; Sophie Bertin; Francis Cogé; Pascale Chomarat; Philippe Delagrange; Bernard Serkiz; Jean-Paul Bouchet; Roger J W Truscott; Jean A Boutin Journal: Biochem J Date: 2005-05-15 Impact factor: 3.857
Authors: Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese Journal: Pharmacol Rev Date: 2010-07-06 Impact factor: 25.468
Authors: Patricia J Lardone; Antonio Carrillo-Vico; María C Naranjo; Beatriz De Felipe; Alejandro Vallejo; Michal Karasek; Juan M Guerrero Journal: J Cell Physiol Date: 2006-01 Impact factor: 6.384
Authors: Carla C Maganhin; Adriana Aparecida Ferraz Carbonel; Juliana Halley Hatty; Luiz Fernando Portugal Fuchs; Itamar Souza de Oliveira-Júnior; Manuel de Jesus Simões; Ricardo S Simões; Edmund C Baracat; José Maria Soares Journal: Rev Assoc Med Bras (1992) Date: 2008 May-Jun Impact factor: 1.209
Authors: D E Blask; D B Pelletier; S M Hill; A Lemus-Wilson; D S Grosso; S T Wilson; M E Wise Journal: J Cancer Res Clin Oncol Date: 1991 Impact factor: 4.553
Authors: Eduardo Alves de Almeida; Paolo Di Mascio; Tatsuo Harumi; D Warren Spence; Adam Moscovitch; Rüdiger Hardeland; Daniel P Cardinali; Gregory M Brown; S R Pandi-Perumal Journal: Childs Nerv Syst Date: 2010-11-21 Impact factor: 1.475
Authors: Chris Minella; Pierre Coliat; Shanti Amé; Karl Neuberger; Alexandre Stora; Carole Mathelin; Nathalie Reix Journal: Cancer Causes Control Date: 2021-11-27 Impact factor: 2.506
Authors: Eleni N Sertaridou; Ioanna G Chouvarda; Konstantinos I Arvanitidis; Eirini K Filidou; George C Kolios; Ioannis N Pnevmatikos; Vasilios E Papaioannou Journal: Ann Intensive Care Date: 2018-12-04 Impact factor: 6.925
Authors: Regina P Markus; Kassiano S Sousa; Sanseray da Silveira Cruz-Machado; Pedro A Fernandes; Zulma S Ferreira Journal: Int J Mol Sci Date: 2021-11-10 Impact factor: 5.923
Authors: Peter G Lawlor; Marie T McNamara-Kilian; Alistair R MacDonald; Franco Momoli; Sallyanne Tierney; Nathalie Lacaze-Masmonteil; Monidipa Dasgupta; Meera Agar; Jose L Pereira; David C Currow; Shirley H Bush Journal: BMC Palliat Care Date: 2020-10-21 Impact factor: 3.234
Authors: Javier Fagundo-Rivera; Regina Allande-Cussó; Mónica Ortega-Moreno; Juan Jesús García-Iglesias; Adolfo Romero; Carlos Ruiz-Frutos; Juan Gómez-Salgado Journal: Healthcare (Basel) Date: 2021-05-30